Consonance Capital Management’s Oxford Immunotec Global OXFD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-1,244,460
Closed -$11.5M – 41
2020
Q1
$11.5M Sell
1,244,460
-1,119,264
-47% -$15.6M 0.86% 25
2019
Q4
$39.2M Buy
2,363,724
+219,200
+10% +$3.55M 2.39% 18
2019
Q3
$35.7M Sell
2,144,524
-199,000
-8% -$2.75M 3.53% 12
2019
Q2
$32.2M Sell
2,343,524
-265,260
-10% -$4.06M 2.28% 16
2019
Q1
$44.9M Buy
2,608,784
+29,000
+1% +$459K 2.84% 12
2018
Q4
$33M Buy
2,579,784
+130,600
+5% +$1.98M 2.42% 14
2018
Q3
$39.8M Buy
2,449,184
+110,000
+5% +$1.57M 2.14% 19
2018
Q2
$30.2M Hold
2,339,184
– – 1.94% 21
2018
Q1
$29.1M Buy
2,339,184
+1,219,297
+109% +$14.8M 2.66% 16
2017
Q4
$15.6M Buy
+1,119,887
New +$16.4M 1.41% 18

Other funds holding OXFD

Consonance Capital Management's OXFD Position: Q2 2020 in Review

Consonance Capital Management sold out of Oxford Immunotec Global (OXFD) in Q2 2020, closing a stake of 1,244,460 shares — an estimated $11.5M sold.

Consonance Capital Management first reported a position in OXFD in Q4 2017 and held it in 10 quarters. The position peaked at $44.9M in Q1 2019. 65 funds tracked by Wall St. Rank hold OXFD as of Q2 2020.

  • Consonance Capital Management reported no remaining Oxford Immunotec Global position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 1,244,460 Oxford Immunotec Global shares in Q2 2020, an estimated $11.5M.
  • Consonance Capital Management first reported a position in Oxford Immunotec Global in Q4 2017 and held it in 10 quarters.
  • Consonance Capital Management's Oxford Immunotec Global position peaked at $44.9M in Q1 2019.
  • 65 funds tracked by Wall St. Rank held Oxford Immunotec Global as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.